Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 65.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.99M |
| Shares Out | 30.72M |
| EPS (ttm) | -1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,942 |
| Open | 2.14 |
| Previous Close | 2.12 |
| Day's Range | 2.08 - 2.19 |
| 52-Week Range | 1.45 - 12.37 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 5.10 (+138.3%) |
| Earnings Date | Aug 8, 2022 |
About SNSE
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SNSE stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 138.32% from the latest price.
News
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
- SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 -
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today...
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today ...
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors -
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
- Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA -
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
Brings decades of both board and management life sciences experience Brings decades of both board and management life sciences experience
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, toda...
Executives Buy Around $1M Of 5 Penny Stocks
The economic sentiment indicator in the Eurozone rose to a 3-month high level of 114 in February, surpassing market estimates of 113.1. Investors, meanwhile, focused on some notable insider trades When ...
Sensei Biotherapeutics to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics Announces Executive Promotions
Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer
Sensei Biotherapeutics Named a Winner of Comparably's Best CEO Award
BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for ...
V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform -
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th An...
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why
Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model –
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
You might not have heard of them, but one went up big while the other served up a massive disappointment.
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal A...
- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs -
5 Stocks With High Guru and Insider Buys in the Past 3 Months
According to the Double Buys page, a Premium feature of GuruFocus, five stocks that had multiple guru and insider buys during the second quarter are PennyMac Financial Services inc. ( PFSI , Financial),...
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patient...
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
- ImmunoPhage™ platform programs and the VISTA program continue to advance -